Premium
Nifedipine in the treatment of hypertension: report of a double‐blind controlled trial.
Author(s) -
Bayley S,
Dobbs RJ,
Robinson BF
Publication year - 1982
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1982.tb02021.x
Subject(s) - nifedipine , medicine , double blind , blood pressure , clinical trial , anesthesia , pharmacology , placebo , alternative medicine , calcium , pathology
1 The effect of oral nifedipine has been examined in patients with hypertension in whom arterial pressure was not adequately controlled by the combination of a beta‐adrenoceptor antagonist (or alpha‐methyldopa) and a diuretic. 2 In 42 patients, nifedipine (10 mg capsules) was added to the existing therapy in a final dose of 20‐60 mg daily. Six patients had to stop the drug on account of side‐effects. In the 36 patients who continued treatment, arterial pressure fell by an average of 24/9 mmHg supine and 26/10 mmHg standing. 3 In 11 of these patients who subsequently completed a double‐blind, cross‐over, placebo controlled trial, nifedipine (30‐60 mg daily) was found to reduce arterial pressure by an average of 19/11 mmHg supine and 21/12 mmHg standing. 4 In all 11 patients who were changed to a sustained release preparation of nifedipine, control of arterial pressure was at least as good as it had been when taking the capsules.